– June 1, 2014
June 1, 2014
View Issues
-
Bendamustine-rituximab compared with R-CHOP or R-CVP for first-line treatment of indolent NHL
In an international, randomized, non-inferiority trial, bendamustine-rituximab proved comparable in overall response rate when compared with R-CHOP or R-CVP in the management of indolent NHL and mantle cell lymphoma. Progression free and overall survival comparisons remain to be determined. Notably, toxicity profiles were significantly different, with higher rates of reported nausea and vomiting with BR and neuropathy and alopecia with R-CHOP/R-CVP. -
Yoga for Mood, Fatigue, and Inflammation in Breast Cancer Survivors
Breast cancer survivors participating in a 12-week yoga program reported decreased fatigue, increased vitality, and improved sleep on multiple scoring systems, but no impact on depressive symptoms. Increased time spent doing yoga led to greater improvements in inflammation, mood, and fatigue. -
Addition of Bevacizumab for Treatment of Platinum-resistant Recurrent Ovarian Cancer
In a trial comparing chemotherapy alone to chemotherapy plus bevacizumab in the treatment of patients with platinium-resistant ovarian cancer, the combination resulted in improved response rates and progression-free survival (PFS) and without a high rate of added toxicity. Whether bevacizumab alone would provide comparable improvements was not assessed but remains an important question for future trials.